HealiusASX:HLS -1.28%54 Debt-to-EBITDA is 5.95 as of Dec. 2025, which is 104% above its 10-year median of 2.91. GuruFocus rates ASX:HLS with a GF Score™ of 54/100 and a GF Value™ of A$1.02 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 113 Medical Diagnostics & Research companies, Healius ranks worse than 884954.87% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Healius's Debt-to-EBITDA or its related term are showing as below:
ASX:HLS'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -19.3 Med: 2.91 Max: 6.65
Current: -2.82
During the past 13 years, the highest Debt-to-EBITDA Ratio of Healius was 6.65. The lowest was -19.30. And the median was 2.91.
ASX:HLS's Debt-to-EBITDA is ranked worse than 100% of 113
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.3
vs ASX:HLS: -2.82
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Healius Debt-to-EBITDA Related Terms
Healius Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Healius's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:HLS vs TMO, DHR, IDXX: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Healius's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Healius Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Healius's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Healius's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Healius (ASX:HLS) has a Debt-to-EBITDA of 5.95 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Healius. This is 104% above median its historical median of 2.91. According to the industry distribution chart, Healius ranks #999999 out of 113 companies in the Medical Diagnostics & Research industry.
Is Healius' Debt-to-EBITDA too high?
Healius' current Debt-to-EBITDA of 5.95 is 104% above median its 10-year median of 2.91. The Medical Diagnostics & Research industry median Debt-to-EBITDA is 2.30. Healius' value of 5.95 is 158.7% above this industry median. Based on the distribution chart, Healius ranks #999999 out of 113 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Healius has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Healius' Debt-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Healius ranks #999999 out of 113 companies for Debt-to-EBITDA. This places Healius in the lower half of its industry. The industry median Debt-to-EBITDA is 2.30. Healius' value of 5.95 is 158.7% above this benchmark. While the company's 10-year median is 2.91 vs. the industry median of 2.30, Healius has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.30, based on 113 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Healius's current Debt-to-EBITDA of 5.95 is 158.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Healius. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Healius's current Debt-to-EBITDA is 5.95, which is 104% above median its own 10-year median of 2.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healius stock overvalued right now?
Based on GuruFocus' analysis, Healius (ASX:HLS) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.02, compared to a current price of A$0.39 — trading 62.3% below its estimated fair value. The current Debt-to-EBITDA is 5.95, which is 104% above median its 10-year median of 2.91 and 158.7% above the Medical Diagnostics & Research industry median of 2.30. Healius' overall GF Score™ is 54/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Healius (ASX:HLS), the current Debt-to-EBITDA is 5.95 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Healius (ASX:HLS) Overvalued in 2026?
Based on GuruFocus' analysis, Healius stock appears to be undervalued.
The current stock price of A$0.39 is trading 62.3% below its estimated GF Value™ of A$1.02.
GuruFocus considers Healius to be Possible Value Trap.
Key valuation signals for ASX:HLS:
Debt-to-EBITDA: 5.95 (104% above median its 10-year median of 2.91)
GF Value™: A$1.02 vs. price of A$0.39 (62.3% below fair value)
Industry Position: 158.7% above the Medical Diagnostics & Research median (#999999 of 113)
No single metric tells the full story. See the ASX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Healius is Australia's second-largest pathology provider. Pathology revenue is almost entirely earned via the public health Medicare system and makes up the majority of Healius' group revenue. A small portion comes from its clinical testing business, Agilex.
54GF Score
Get the complete analysis for ASX:HLS
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:HLS has been successfully added to your 
